REMEGEN CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.5 HKD | +0.83% |
|
+10.11% | -18.56% |
| Apr. 26 | RemeGen Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 04 | Remegen Gets US FDA Fast Track Designation for Primary Sjögren's Syndrome Medication | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 39,166 | 31,092 | 36,877 | 28,299 | 25,200 | - | - |
| Enterprise Value (EV) 1 | 36,595 | 29,387 | 34,808 | 28,741 | 26,207 | 27,016 | 27,846 |
| P/E ratio | -56.1 x | 111 x | -27.2 x | -11.9 x | -13.4 x | -22.5 x | -58.6 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | 21.8 x | 48 x | 26.1 x | 14.9 x | 10.1 x | 7.63 x |
| EV / Revenue | - | 20.6 x | 45.3 x | 26.5 x | 15.5 x | 10.9 x | 8.43 x |
| EV / EBITDA | -60.4 x | 80.3 x | -43.8 x | -21.7 x | -28.8 x | -68.6 x | 232 x |
| EV / FCF | -33.2 x | -83.6 x | -17.2 x | -12.2 x | -18.7 x | -36.3 x | -133 x |
| FCF Yield | -3.02% | -1.2% | -5.8% | -8.2% | -5.35% | -2.76% | -0.75% |
| Price to Book | 10.9 x | 8.98 x | 3.64 x | 5.34 x | 5.47 x | 6.74 x | 8.27 x |
| Nbr of stocks (in thousands) | 489,837 | 489,837 | 539,197 | 538,532 | 537,914 | - | - |
| Reference price 2 | 79.96 | 63.47 | 51.14 | 34.04 | 28.23 | 28.23 | 28.23 |
| Announcement Date | 3/26/21 | 2/20/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | 1,426 | 767.8 | 1,083 | 1,690 | 2,489 | 3,304 |
| EBITDA 1 | - | -605.6 | 365.8 | -794.1 | -1,322 | -908.5 | -393.9 | 120.2 |
| EBIT 1 | - | -668.6 | 281.6 | -980.9 | -1,502 | -907.6 | -215.3 | 84.5 |
| Operating Margin | - | - | 19.74% | -127.76% | -138.65% | -53.7% | -8.65% | 2.56% |
| Earnings before Tax (EBT) 1 | - | -697.8 | 276.3 | -998.8 | -1,511 | -1,152 | -684.4 | -281.5 |
| Net income 1 | -430.3 | -697.8 | 276.3 | -998.8 | -1,511 | -1,148 | -688.2 | -272.5 |
| Net margin | - | - | 19.37% | -130.09% | -139.55% | -67.9% | -27.65% | -8.25% |
| EPS 2 | - | -1.425 | 0.5700 | -1.880 | -2.860 | -2.114 | -1.256 | -0.4819 |
| Free Cash Flow 1 | - | -1,104 | -351.4 | -2,019 | -2,356 | -1,401 | -744.9 | -209 |
| FCF margin | - | - | -24.64% | -263% | -217.51% | -82.89% | -29.93% | -6.33% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 10/28/20 | 3/26/21 | 2/20/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 |
|---|---|---|---|---|---|---|---|
| Net sales | - | 1,397 | - | - | 198.1 | 419 | - |
| EBITDA | - | - | - | - | - | - | - |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | 720.3 | - | - | - | -509.7 | - |
| Net income 1 | -444 | - | -489.1 | -199.1 | - | -509.7 | -323.8 |
| Net margin | - | - | - | - | - | -121.65% | - |
| EPS 2 | -0.9100 | - | -0.9600 | -0.3600 | - | - | -0.6000 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/23/21 | 2/20/22 | 8/30/22 | 10/27/22 | 2/27/23 | 2/27/23 | 4/27/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 442 | 1,007 | 1,816 | 2,645 |
| Net Cash position 1 | - | 2,571 | 1,704 | 2,069 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.3342 x | -1.108 x | -4.611 x | 22 x |
| Free Cash Flow 1 | - | -1,104 | -351 | -2,019 | -2,356 | -1,401 | -745 | -209 |
| ROE (net income / shareholders' equity) | - | -41.5% | 7.85% | -23.7% | -35.5% | -38.9% | -37.5% | -25.3% |
| ROA (Net income/ Total Assets) | - | -29% | 6.68% | -19.6% | -26.2% | -19.9% | -11.9% | -6.52% |
| Assets 1 | - | 2,403 | 4,138 | 5,090 | 5,775 | 5,768 | 5,779 | 4,179 |
| Book Value Per Share 2 | - | 7.340 | 7.070 | 14.00 | 6.380 | 5.160 | 4.190 | 3.410 |
| Cash Flow per Share 2 | - | -1.620 | 0.5400 | -2.380 | - | -1.730 | -0.5100 | -0.1000 |
| Capex 1 | - | 443 | 615 | 756 | 853 | 516 | 350 | 250 |
| Capex / Sales | - | - | 43.12% | 98.41% | 78.74% | 30.55% | 14.07% | 7.58% |
| Announcement Date | 10/28/20 | 3/26/21 | 2/20/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
28.23
CNY
Average target price
39.93
CNY
Spread / Average Target
+41.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.56% | 3.48B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 9995 Stock
- Financials RemeGen Co., Ltd.
